Company - Boehringer Ingelheim Therapeutics in Germany, Ochsenhausen
family owned company, Ochsenhausen, Germany, expertise in virology, microbiology and cell culture, cell culture, immunology, laboratory capacits, gmp manufacturing, biosafety testing, GxP, GLP, GMP
415
page-template,page-template-full_width,page-template-full_width-php,page,page-id-415,page-parent,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,footer_responsive_adv,qode-child-theme-ver-1.0.0,qode-theme-ver-13.6,qode-theme-bridge,disabled_footer_top,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

History

Founded in 1971, Boehringer Ingelheim Therapeutics formerly known as Labor Dr. Merk & Kollegen is based in Ochsenhausen, Germany and was a family owned company, performing R&D and clinical manufacturing with a focus on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatments.before being acquired by Boehringer Ingelheim in 2021.

About us

As of march 2021, Labor Dr. Merk and Kollegen GmbH became a part of the Boehringer Ingelheim family and operates under the new company name Boehringer Ingelheim Therapeutics GmbH which performs R&D and clinical manufacturing with a focus on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatments.

History

Founded in 1971, Boehringer Ingelheim Therapeutics formerly known as Labor Dr. Merk & Kollegen is based in Ochsenhausen, Germany and was a family owned company, performing R&D and clinical manufacturing with a focus on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatments.before being acquired by Boehringer Ingelheim in 2021.

About us

As of march 2021, Labor Dr. Merk and Kollegen GmbH became a part of the Boehringer Ingelheim family and operates under the new company name Boehringer Ingelheim Therapeutics GmbH which performs R&D and clinical manufacturing with a focus on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatments.

Facilities

With over 3600 m² state of the art laboratory capacity and a 300 m² GMP production site, our facilities encompass space for end-to-end process development, manufacturing and biosafety testing.

Quality Standards

Guaranteeing excellent quality concerning all activities is our top priority.

Facilities

With over 3600 m² state of the art laboratory capacity and a 300 m² GMP production site, our facilities encompass space for end-to-end process development, manufacturing and biosafety testing.

Quality Standards

Guaranteeing excellent quality concerning all activities is our top priority.